Repare Therapeutics Insiders Establish New and Modified Automatic Securities Disposition PlansBusiness Wire • 12/15/21
Repare Therapeutics Inc. (RPTX) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/10/21
Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial ResultsBusiness Wire • 11/10/21
Repare Therapeutics Announces Closing of Upsized Offering of Common Shares and Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness Wire • 11/02/21
Repare Therapeutics to Participate at the H.C. Wainwright 2nd Annual Precision Oncology ConferenceBusiness Wire • 10/18/21
Repare Therapeutics Reveals Early Efficacy Data From Lead Program In Solid Tumor SettingBenzinga • 10/11/21
Repare Therapeutics Presents Preliminary Phase 1 Monotherapy Clinical Data from the Ongoing First-in-Human Phase 1/2 TRESR Study of RP-3500 in Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBusiness Wire • 10/08/21
Repare Therapeutics Issues Statement Regarding Inadvertent Issuance of Phase 1/2 TRESR RP-3500 Clinical Trial Abstract by the AACR-NCI-EORTC Virtual International ConferenceBusiness Wire • 10/07/21
Repare Therapeutics to Present Initial Data from the Phase 1/2 TRESR RP-3500 Clinical Trial at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer TherapeuticsBusiness Wire • 09/30/21
Repare Therapeutics to Participate at the 19th Annual Morgan Stanley Virtual Global Healthcare ConferenceBusiness Wire • 09/02/21
Repare Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial ResultsBusiness Wire • 08/12/21
Repare Therapeutics to Participate at the 42nd Annual Goldman Sachs Virtual Global Healthcare ConferenceBusiness Wire • 06/02/21
Repare Therapeutics Provides Business Update and Reports First Quarter 2021 Financial ResultsBusiness Wire • 05/13/21
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1Business Wire • 05/03/21
Repare Therapeutics to Present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor ConferenceBusiness Wire • 04/13/21
Repare Therapeutics to Highlight Program Progress for RP-6306 at Today's Virtual Investor Day EventBusiness Wire • 04/08/21
Repare Therapeutics to Introduce RP-6306, a Potent and Specific Inhibitor of a Novel Target, at Virtual Investor Day on April 8Business Wire • 03/30/21
Valence Discovery to Support Repare Therapeutics on AI-Enabled Drug Discovery in Precision OncologyBusiness Wire • 03/17/21
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial ResultsBusiness Wire • 03/04/21